<DOC>
	<DOCNO>NCT01005472</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving temozolomide together sunitinib malate may kill tumor cell . Phase II never conduct due toxicity phase I . PURPOSE : This phase I/II trial study side effect best dose sunitinib malate give together temozolomide see well work treat patient stage III stage IV malignant melanoma .</brief_summary>
	<brief_title>Temozolomide Sunitinib Malate Treating Patients With Stage III Stage IV Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess maximum tolerate dose sunitinib malate administer concurrently temozolomide patient stage IIIC IV malignant melanoma . ( Phase I ) - Assess overall safety regimen patient . ( Phase I ) - Determine response rate patient treat regimen . ( Phase II ) Phase II never conduct due toxicity phase I . Secondary - Determine response rate patient treat regimen . ( Phase I ) - Determine safety tolerability regimen patient . ( Phase II ) - Determine progression-free survival patient treat regimen . - Determine overall survival patient treat regimen . OUTLINE : This phase I , dose-escalation study sunitinib malate follow phase II study . Patients receive oral sunitinib malate daily oral temozolomide daily day 1-42 . Treatment repeat every 56 day 1 year absence disease progression unacceptable toxicity . After completion study therapy , patient follow 6 month 5 year . Phase II never conduct due toxicity phase I .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirm Stage IIIC unresectable cutaneous mucosal melanoma measureable disease stage IV cutaneous , mucosal ocular melanoma measureable disease . ECOG performance status 02 age great equal 18 year ANC ≥ 1,500/µL Platelet count ≥ 100,000/µL Hemoglobin ≥ 10.0 g/dL Creatinine ≤ 2 time upper limit normal ( ULN ) Total bilirubin ≤ 2 time ULN LDH ≤ 5 time ULN AST ALT ≤ 2.5 time ULN ( ≤ 5 time ULN liver metastasis present ) LVEF ≥ 50 % screen ECHO woman childbearing potential must negative urine serum pregnancy test upto 28 day prior commencement dosing . Fertile patient must use effective contraception ≥ 6 month completion study treatment Willing able comply schedule visit , treatment plan , laboratory test , study procedure study entry , write informed consent must obtain . Written informed consent must obtain patient prior perform study related procedure . Exclusion Criteria pregnant nursing follow within past 12 month : Myocardial infarction Severe and/or unstable angina Coronary and/or peripheral artery bypass graft Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Pulmonary embolism ongoing cardiac dysrhythmias ≥ grade 2 , accord NCI CTCAE v3.0 prolong QTc interval baseline EKG uncontrolled hypertension ( i.e. , blood pressure &gt; 150/100 mm Hg despite optimal medical therapy ) preexist thyroid abnormality thyroid function maintain normal range medication know clinically uncontrolled infectious disease , include HIV positivity AIDSrelated illness severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result , , judgment investigator , would make patient inappropriate study entry prior chemotherapy melanoma , except chemotherapy give isolated limb perfusion stage IIIC disease Prior adjuvant immunotherapy and/or immunotherapy metastatic disease allow prior major surgery , radiotherapy , immunotherapy within 4 week start therapy treatment potent CYP3A4 inhibitor 7 day study dose treatment potent CYP3A4 inducers 12 day study dose concurrent treatment another clinical trial ( Concurrent participation supportive care trial nontreatment trial ( e.g. , qualityoflife trial ) allow ) . concurrent chemotherapy , immunotherapy , biological therapy , investigational drug concurrent drug dysrhythmic potential , include follow : Terfenadine Quinidine Procainamide Disopyramide Sotalol Probucol Bepridil Haloperidol Risperidone Indapamide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
</DOC>